Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
LAB Stock Chart & Stats
$1.63
>-$0.01(-0.28%)
At close: 4:00 PM EST
$1.63
>-$0.01(-0.28%)
Day’s Range― - ―
52-Week Range$0.92 - $2.25
Previous CloseN/A
Volume335.74K
Average Volume (3M)1.39M
Market Cap
$626.84M
Enterprise Value$248.13M
Total Cash (Recent Filing)$194.90M
Total Debt (Recent Filing)$27.39M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Feb 18, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding384,565,400
10 Day Avg. Volume1,634,197
30 Day Avg. Volume1,385,775
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.31
Price to Sales (P/S)3.54
P/FCF Ratio-4.07
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-2.65
Forecast
1Y Price Target
$1.35Price Target Upside-17.18% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost Reduction MeasuresAnnounced restructuring and $40M cost actions have been implemented and should support the profit and loss statement.
Divestiture BenefitsThe divestiture is expected to generate approximately $350 million in upfront cash, which should support the company's core M&A strategy.
Future Earnings PotentialManagement expects they can reach positive adjusted EBITDA by the end of 2026 despite the tough macro environment.
Bears Say
Growth OutlookThe sale of SomaLogic is expected to lead to a lower growth outlook for the company and less visibility on potential catalysts.
Market HeadwindsThe business is facing higher exposure to ongoing market headwinds, including US Academic funding and soft capital expenditure trends.
Revenue ChallengesThe difficult macro environment for academic customers and instruments persists, affecting the company's revenue.
Standard BioTools News
LAB FAQ
What was Standard BioTools’s price range in the past 12 months?
Standard BioTools lowest stock price was $0.92 and its highest was $2.25 in the past 12 months.
What is Standard BioTools’s market cap?
Standard BioTools’s market cap is $626.84M.
When is Standard BioTools’s upcoming earnings report date?
Standard BioTools’s upcoming earnings report date is Feb 18, 2026 which is in 57 days.
How were Standard BioTools’s earnings last quarter?
Standard BioTools released its earnings results on Nov 04, 2025. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.043 by -$0.047.
Is Standard BioTools overvalued?
According to Wall Street analysts Standard BioTools’s price is currently Overvalued.
Does Standard BioTools pay dividends?
Standard BioTools does not currently pay dividends.
What is Standard BioTools’s EPS estimate?
Standard BioTools’s EPS estimate is -0.05.
How many shares outstanding does Standard BioTools have?
Standard BioTools has 384,565,400 shares outstanding.
What happened to Standard BioTools’s price movement after its last earnings report?
Standard BioTools reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.043. Following the earnings report the stock price went down -4.202%.
Which hedge fund is a major shareholder of Standard BioTools?
Currently, no hedge funds are holding shares in LAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Standard BioTools Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.35 (-17.18% Downside)
$1.35 (-17.18% Downside)
Hedge Fund Trend
Decreased
By 162.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $14.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.6%
Last 30 Days ▲ 23.9%
Last 30 Days ▲ 23.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-29.44%
12-Months-Change
Fundamentals
Return on Equity
-24.63%
Trailing 12-Months
Asset Growth
-21.41%
Trailing 12-Months
Company Description
Standard BioTools
Standard BioTools Inc. (LAB) is a biotechnology company focused on advancing the field of genomics and proteomics through innovative tools and technologies. The company specializes in developing and commercializing advanced instruments and reagents that enable researchers and clinicians to perform high-throughput analysis of biological samples. Standard BioTools operates primarily in the life sciences sector, providing solutions for applications in drug discovery, clinical diagnostics, and personalized medicine.
LAB Stock 12 Month Forecast
Average Price Target
$1.35
▼(-17.18% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---